TO THE EDITOR
We note the recent article from Park et al. (2007) reports a dose-dependent ACTH induction of the immunomodulatory factor IL-18 in HaCaT keratinocytes. Experiments were conducted, which implicated both melanocortin-1 receptor (MC1R) and melanocortin-2 receptor (MC2R) in this cellular response. Although the authors show a clear abolition of IL-18 production by pre-treatment with MC2R antibody, no statistically significant effect was reported for MC1R antibody pre-treatment. The involvement of MC1R in the mediation of this response was largely inferred by the apparent detection of MC1R protein in HaCaT keratinocytes by Western immunoblotting. There are, however, considerable technical issues regarding the use of antibodies against MC1R, which can unwittingly lead to the misidentification of MC1R protein expression. Therefore, despite the accumulation of numerous reports describing the presence of MC1R in various non-melanocytic human skin cells, methodological concerns ensure that this topic is still controversial.
In this regard, we reported recently (Roberts et al., 2006 ) that we were unable to detect MC1R in HaCaT keratinocytes by immunoblotting using the same antibody as Park et al. in Figure 5a of their paper. Our experimentation facilitated specific MC1R detection by use of both negative (parental HEK) and positive (MC1R-transfected HEK) control cells for identification of the correct size band. Furthermore, we implemented MC1R peptide blocking to distinguish the specific signal from the numerous non-specific bands obtained with this antibody. Such controls were not evident in the report by Park et al. Moreover, we revealed that HaCaT keratinocytes, in contrast to melanocytes, were negative for MC1R expression using both a sensitive radioligand binding assay, and a functional cAMP assay (Roberts et al., 2006) .
Unambiguous detection of MC1R in human cell types is technically demanding, mainly owing to the extremely low levels at which MC1R mRNA and protein are expressed. The best characterized human cell type known to express MC1R, the melanocyte, does so at only 700-1000 receptors per cell (Donatien et al., 1992; Roberts et al., 2006) . This low abundance is readily apparent when comparison is made with either tyrosinase, which is present at the order of 10 6 -10 7 molecules per human melanocyte, or with mouse MC1R at approximately 10 4 receptors per cell (Siegrist et al., 1991) . Other non-melanocytic human cells, if expressing MC1R protein, would be expected to do so at levels even lower than that within melanocytes. Indeed, we have quantitated MC1R mRNA levels in various cultured human skin cells and found that mRNA expression is at least 11-fold lower than that in melanocytes (Roberts et al., 2006) . If this expression was translated into functional receptor, then detection of such a low level of protein would require methodology that provided enormous sensitivity as well as extensive controls to ensure specificity. In our experience, some of the most common techniques used by authors to report MC1R expression are simply inadequate to detect such low receptor levels with the requisite specificity.
In carefully controlled experiments, we found the antibody-based immunoblotting and immunofluorescence procedures were not sensitive enough to detect an MC1R signal in human melanocytes (Roberts et al., 2006 (Sturm et al., 2003) and others (Eberle, 1988; Schioth et al., 1996) have shown that this leads to mass aggregation of the MC1R protein and consequent retarded gel migration. It is, however, uncertain from their methodological description whether Park et al. also boiled their cell extracts. Immunofluorescence is generally less sensitive than immunoblotting, as the cells cannot be concentrated and there is no size discrimination of the signal. A sensitive technique that does not involve antibody detection is radioligand binding. Our laboratory, and others (Donatien et al., 1992; Suzuki et al., 1996) have identified previously MC1R on human melanocytes using this technique, with the presence of the receptor evident from high affinity, saturable binding that can be specifically competed by unlabeled melanocortins. In our studies, parental HEK, HaCaT and primary keratinocyte, and fibroblast cells did not display these characteristics leading to the conclusion that MC1R protein is absent from the surface of these cells (Roberts et al., 2006) . Another technique which circumvents the sensitivity and specificity issues beset by antibody-mediated detection of MC1R protein is the analysis of cAMP production following activation of MC1R. This functional assay further indicated that HaCaT cells did not harbor active MC1R (Roberts et al., 2006) .
Since our recent documentation of the literature with respect to MC1R expression in non-melanocytic human Abbreviations: MC1R, melanocortin-1 receptor; MC2R, melanocortin-2 receptor cells (Roberts et al., 2006) , more reports describing such expression have emerged (Gatti et al., 2006; Manna et al., 2006; Hoch et al., 2007; Park et al., 2007) , whereas other articles have concluded that MC1R is limited to cutaneous melanocytes only (Li et al., 2006) . Owing to this conflict, it is imperative that future reports be quantitative and include appropriate technical controls that identify the apparent MC1R signal to be specific, and where possible compare this signal relative to known positive and negative control cell types. Correlation of protein expression data with functional responses will further facilitate accurate assessment of the roles that MC1R may play beyond its involvement in pigmentation.
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